[The profile of the patients referred by general practitioners to respiratory physicians for assessment of undiagnosed bronchial disease]. / Profil des patients adressés par les médecins généralistes aux pneumologues pour bilan d'une bronchopathie non diagnostiquée - résultats de l'étude Bilan.

INTRODUCTION: In general practice, COPD is often under-diagnosed and inappropriate pharmacological treatment given. OBJECTIVES: To determine the profile of patients over 40 years old, smokers or ex-smokers, referred by general practitioners to respiratory physicians for assessment of undiagnosed bronchial disease. METHODS: Observational study carried-out among 103 respiratory physicians in France in 2007. RESULTS: The diagnosis of COPD was confirmed by the respiratory physicians in 433/486 (89%) patients. COPD patients were aged 61 years on average, male (63%) and often current smokers (46%). Most of them had more than three respiratory symptoms. The diagnosis of COPD was made after a long history of symptoms. We found 148 (34.2%) COPD patients with a FEV(1)/FVC greater than 0.7 and were classified as mild (61 patients), moderate (77 patients) or severe (10 patients). CONCLUSIONS: In patients at risk, smokers or ex-smokers with respiratory symptoms, COPD was the diagnosis most often confirmed by the respiratory physician. A significant proportion of respiratory physicians diagnosed and assessed the severity of COPD, not strictly on the basis of national recommendations, but rather on the association of risk factors, respiratory symptoms and even isolated changes in FEV(1).

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.

Inhalation of on-demand salbutamol (ODS) several times daily is sometimes the only beta2-agonist prescribed in moderate persistent asthma, whereas a long-acting beta2-agonist should be added. This trial aimed to compare the efficacy of formoterol dry-powder capsule 12 microg b.i.d. (Foradil) and ODS in patients with moderate persistent asthma treated with inhaled corticosteroids, in the conditions of real practice. Two hundred and fifty-nine patients were randomized (formoterol; 130; ODS: 129) in this open, parallel-group trial. The mean increases in morning peak expiratory flow (PEF primary variable) and evening PEF over the 3-month treatment period were statistically significantly higher with formoterol: +25.7 and +24.1 l min(-1), respectively vs. +4.5 and +0.5 l min(-1) respectively with ODS. The increase in FEV1 was statistically significantly higher with formoterol at months 1 and 3. Formoterol reduced the use of salbutamol as rescue medication by two-thirds. The percentages of symptom-free days and nights statistically significantly increased with formoterol (+20% and +33% respectively), but did not significantly change with ODS. Clinically relevant and statistically significant improvement in the mean total score of the St George's Hospital Respiratory Questionnaire was observed in the formoterol group. Adverse events were similar in the two groups. The results show that treatment with formoterol has significant advantages over ODS in patients with moderate persistent asthma.

Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease.

The main purpose of this study was to assess whether pharmacological treatments prescribed by respiratory physicians to patients with chronic obstructive pulmonary disease (COPD) were consistent with the guidelines. The treatments prescribed by respiratory physicians to 631 consecutive patients with COPD, compared to 879 asthmatics were prospectively recorded. All subjects underwent peak expiratory flow rate measurement, spirometry and assessment of recent evolution and dyspnoea (visual analogue and Medical Research Council scales). Patients with COPD received more treatments than asthmatics (mean+/-SD: 2.6+/-0.5 versus 2.2+/-0.4, p<0.0001). Treatments administered to patients with COPD were beta2-agonists in 78% (versus 94% in asthmatics), anticholinergic agents (AC) in 56% (versus 16% in asthma), methylxanthines in 31% (versus 15% in asthma) and inhaled corticosteroids in 76% (versus 85% in asthma). Intensity of treatment was influenced by disease severity for all treatments except AC. In conclusion, pharmacological treatment of chronic obstructive pulmonary disease by respiratory physicians is only partially consistent with current guidelines, with a high proportion of inhaled corticosteroid prescriptions and a relative under-use of anticholinergic agents; this most likely reflects the persistent uncertainties of physicians, and emphasizes that more efforts are required to improve implementation of chronic obstructive pulmonary disease guidelines and assess the efficacy and cost-effectiveness of recommended strategies.

[Postpneumonectomy syndrome in adults: description and therapeutic propositions apropos of 8 cases]. / Syndrome postpneumonectomie de l'adulte. Description et propositions thérapeutiques à propos de 8 observations.

BACKGROUND: Adult post-pneumonectomy syndrome can be defined as an extrinsic compression of the main bronchus or a lobe bronchus on the aorta resulting from excessive mediastinal deviation after pneumonectomy. PATIENTS: Eight cases in adults are reported. The delay to symptom onset was a mean 34 months. Three patients complained of increased dyspnea and 5 patients experienced a must more rapid course with adult respiratory distress syndrome in 1. Fibroscopy and chest CT confirmed the diagnosis of extrinsic compression of the main bronchus or a lobe bronchus. RESULTS: In the first 2 patients, endoscopic treatment with an endobronchial prosthesis was unsuccessful. The mediastinum was recentered in the following patients using an inflatable prosthesis positioned in the pneumonectomy cavity. Clinical improvement was achieved in all patients. Fibroscopy and chest CT confirmed the reduction in bronchial compression. DISCUSSION: Early diagnosis and mediastinal recentering are required for good outcome. Surveillance after pneumonectomy should include a search for mediastinal deviation and its consequences, particularly concerning the permeability of the remaining bronchi.

[Pulmonary resections for cancer in the octogenarian]. / Résections pulmonaires pour cancer chez l'octogénaire.

UNLABELLED: More and more elderly subjects are offered for pulmonary resection. The object of this study was to review the results of excision for cancer in octogenarians. PATIENTS: 51 consecutive patients (44 men, 7 women) with a mean age of 82 years (80-91) were operated on. 31 lobectomies, 2 bilobectomies, 13 pneumonectomies, 1 segmental resection and 4 exploratory thoracotomies were carried out. 17 tumours were classed as stage I, 15 as stage II and 15 as stage III. RESULTS: 38 patients (75%) had uncomplicated post-operative periods; the predicted factors for complication were the existence of weight loss and alteration of respiratory function. 2 patients (4%) died in the post-operative phase. Neither the type of operation, the staging or the existence of cardiovascular dysfunction had any influence on the post-operative phase. The level of the survival at 3 and 5 years was 39% and 16% respectively. 30% of the late deaths were related to intercurrent events. CONCLUSIONS: Pulmonary excision may be envisaged in an octogenarian who is in good physical and intellectual state with a limited tumour. This surgery in general is applied to a population which probably only marginally consists of octogenarians but the results here justify their inclusion in the indications for selection.

Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors.

STUDY DESIGN: To determine the long-term results after surgical treatment of bronchioloalveolar lung carcinoma (BALC) and to identify prognostic factors. PATIENTS AND METHODS: A retrospective study of 70 patients (49 men, 21 women), mean age 61+/-10 years, was carried out. Their carcinomas were classified into three clinicopathologic types: nodular or tumoral, pneumonic, and diffuse types. All the diagnosed BALC cases were reviewed and were classified into histologic types: mucinous, nonmucinous (including fibrotic center), and mixed tumors. Univariate and multivariate analyses were carried out. RESULTS: The nodular or tumoral type was identified in 42 patients, pneumonic in 21, and diffuse in seven. Histologically, there were 36 mucinous, 25 nonmucinous, and nine mixed tumors. Resection was complete in 61 instances (87%) and incomplete in five. The 5-year survival rate was 34% in patients with curative resections. Five prognostic factors were identified by univariate analysis, but in multivariate analysis, only three factors remained significant: the absence of symptoms, the TNM stage, and completeness of resection. Thirty-six patients with curative resection (59%) developed recurrences (in the lung in 26 patients; mediastinal lymph nodes, four; distant metastases, nine). The frequency of recurrence was significantly greater in patients with pneumonic-type BALC than in nodular or tumoral types (p<0.01), and pulmonary recurrences were significantly more frequent in pneumonic than in tumoral types (p<0.02). CONCLUSIONS: This study confirmed that the overall prognosis of BALC is not significantly different from that of the other non-small cell lung cancers. We found that the lungs are the predominant site of recurrence in BALC, especially in the pneumonic types. The complete surgical resection of localized BALC offers the best chances of long-term survival.

[Endobronchial lipomas. Apropos of 16 cases]. / Les lipomes endobronchiques. A propos de 16 observations.

Intrabronchial lipomas are rare and benign tumours. Sixteen cases treated between 1956 and 1988 at the Marie Lannelongue Surgical Centre, Paris, are reviewed. The patients presented with various symptoms such as cough, haemoptysis, infection or dyspnoea. Radiography was abnormal in 15 cases, and the lesion was regularly located at bronchoscopy. Treatment was chiefly surgical. Owing to the slow and silent growth of intrabronchial lipomas, there is a risk of progressive bronchial obstruction resulting in bronchopulmonary lesions. With an early detection, treatment should be as conservative as possible.

Bronchial leiomyoma: report of a case successfully treated by endoscopic neodymium-yttrium aluminum garnet laser.

A 40-year-old woman was admitted with dyspnea and episodes of bronchial infection. Leiomyoma of the right lateral basal bronchus was diagnosed and partially removed by a biopsy forceps, and neodymium-yttrium aluminum garnet laser therapy successfully destroyed the rest of this mass.

Principles for safety in application of neodymium-YAG laser in bronchology.

The YAG laser is being used more often in cases of nonresectable bronchogenic cancer and in some cases is called on in lieu of surgery for tracheal stenosis. Patient safety hinges first on the endoscopist's technical skill and second on his understanding of the dangers involved in laser therapy. This report is based on experience gleaned from a 1,503 case series of endoscopic YAG laser treatments on 839 patients. These treatments were carried out by seven endoscopists in four teams using exactly the same equipment and techniques. In spite of the use of this high-risk technique in a high-risk patient population comprising a majority of major airways malignancy, the mortality rate was only 0.4 percent (six deaths: all in the postoperative period). We attribute this success to careful screening prior to resection, whenever possible, and above all to our methodology which not only emphasizes prevention but also enables rapid response.